Use of activated T-cells and a PD-1 antagonist in the manufacture of a medicament for inducing an immune response to a tumour antigen of interest for treating said tumour, wherein the tumour is a melanoma. The PD-1 antagonist can be an anti-PD-1, anti-PD-L1 or anti-PD-L2 antibody or inhibitory antisense RNA to PD-1, PD-L1 or PD-L2.